Key facts
- Afynia’s last known valuation is $6.0M (Nov 2023).
- It has raised $4.6M.
- Notable investors include SOSV, Gaingels, IndieBio, Federal Economic Development Agency for Southern Ontario, Innovation Factory (Hamilton) — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Afynia
- ·The full record, as it builds
Funding rounds
No funding rounds for Afynia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Afynia
Developer of a diagnostic blood test designed to detect endometriosis in people assigned female at birth. The company offers a panel of blood biomarkers that are specific to endometriosis, a proprietary algorithm to assist physicians in identifying people who are likely to have endometriosis, enabling healthcare professionals to provide a diagnosis for endometriosis more easily, which can lead to improved treatment and quality of life.
- Sector
- Healthcare
- HQ
- Hamilton, Canada
- Founded
- 2021
- Employees
- 9
- Website
- afynia.com/
- Ownership
- Privately Held (backing)
Afynia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Afynia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Afynia in its N-PORT filings yet. We sweep new filings monthly.